KRAS and neoplasm: In another study, Dunbar and collaborators did a large-scale analysis to determine if tumor-specific genomic events could be related to CAT risk and found that somatic mutations of genes were associated with heightened malignant aggressiveness: STK11, KRAS, CTNNB1, KEAP1, CDKN2B, and MET were all associated with increased risk in patients with solid tumors [12].